Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.
about
Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption.Axonal α7 nicotinic ACh receptors modulate presynaptic NMDA receptor expression and structural plasticity of glutamatergic presynaptic boutonsChemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depressionNicotinic receptor modulation to treat alcohol and drug dependenceBronchodilatory and anti-inflammatory effects of ASM-024, a nicotinic receptor ligand, developed for the treatment of asthmaASM-024, a piperazinium compound, promotes the in vitro relaxation of β2-adrenoreceptor desensitized tracheasVarenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatumEvaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.Therapeutics for cognitive agingRole for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian miceThe nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in ratsMuscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophreniaNeurobiology of nAChRs and cognition: a mini review of Dr. Jerry J. Buccafusco's contributions over a 25 year career.Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitizationEffects of nicotine on depressive-like behavior and hippocampal volume of female WKY rats.Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.Nicotine: specific role in angiogenesis, proliferation and apoptosis.Opposing actions of ethanol and nicotine on microRNAs are mediated by nicotinic acetylcholine receptors in fetal cerebral cortical-derived neural progenitor cellsAdministration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats.Decreasing nicotinic receptor activity and the spatial learning impairment caused by the NMDA glutamate antagonist dizocilpine in rats.New Insights into the Mechanisms of Action of Cotinine and its Distinctive Effects from Nicotine.Alzheimer's disease and age-related memory decline (preclinical)Allosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors.α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function miceRole of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.Design and Synthesis of Nicotinic Acetylcholine Receptor Antagonists and their Effect on Cognitive Impairment.Low concentrations of nicotine differentially desensitize nicotinic acetylcholine receptors that include α5 or α6 subunits and that mediate synaptosomal neurotransmitter releasePharmacokinetic strategies for treatment of drug overdose and addiction.Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake.Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain.Anxiolytic- and antidepressant-like effects of the methadone metabolite 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP).Pharmacokinetics of cotinine in rats: a potential therapeutic agent for disorders of cognitive function.Improvement of attentional function with antagonism of nicotinic receptors in female rats.Nicotinic receptors in neurodegeneration.Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal functionα4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.Potential therapeutic uses of mecamylamine and its stereoisomers.Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.Complex relationships of nicotinic receptor actions and cognitive functions.
P2860
Q21129280-F92AFF5B-6BC4-430F-B752-612FB0AF8E73Q24601769-B5F71CC9-2F3C-4CDC-9011-E63AF9E1D513Q24630903-4FC0E41B-7AF3-43CB-895A-D49E628BD51EQ28087047-136C6AD0-0017-444B-948F-6D7B65B9D254Q28539013-C8A890F8-E6A6-4909-A02C-1E9C49149B83Q28544879-36E6D9AE-129D-4460-996F-037108B447D5Q28576280-C8F39AD1-CBE0-4D6D-8755-BD97395C6BDCQ30416730-DB36A556-4D04-4C9A-BB68-A050A459A5B5Q30432019-14D95C89-8FB5-4A68-96FA-16CC8FC2F1A2Q30450052-53BD5BC1-1A5A-487F-AD7D-7115A7160ED3Q30455777-4C362339-1DE3-4C0E-BD04-C6AEEF079DEEQ30459624-2AF384B8-6191-4BA6-92FA-E92231C7C495Q30462470-657BFE07-24E0-46C0-99B0-EA99DDE86816Q30475334-EF1C3EE0-A045-4664-AC3B-528F62FC8090Q33624583-E538AF85-C5EA-480E-A003-1DD4C5627DEBQ34112026-B36C4624-FB88-4224-886B-EFB5AE7A9178Q34229828-0E900EDD-C899-4C35-9137-8F51B3EC3E64Q34264318-58BBD63B-14CE-43DD-B033-8C6D39003551Q34266602-A35658CA-7EDF-4205-9D56-8865DBDC39B0Q34287941-7BDA7621-DDB6-4261-9004-FA7166DC2690Q34426718-8B7AF23C-A64C-4054-A687-BA9809627F6EQ35041190-41268B98-30E5-446C-99B1-5242FB1A85C4Q35182101-A2483F86-E86B-49B3-A0EA-C8598A28C9B0Q35264378-16262630-62F4-4C06-A1F9-ED3560415D1FQ35533526-7539ED06-3416-4537-8168-6464A313790CQ35690145-8D8C1A1D-D95B-467F-937D-43823F993DDCQ35733853-7133C62C-979E-4156-819F-3EAF55286BF4Q35753943-09FB80F2-6378-401C-9D9B-4F409E96D25FQ35813574-DC950CD8-B983-4FB5-9995-79C885CABCC7Q35974049-DE34170C-04E6-49D1-88FD-3713A1C086A0Q36335508-06880612-4B5B-4FAA-9548-D216B617E6CEQ36378201-B23ADB07-0A58-4237-9A6E-5D45330A7775Q36576018-32BE4790-1302-4780-BE41-5D66AA6B3967Q36760729-B0D58FE7-0F01-43BC-BE9C-F1547255A068Q36828916-6DEC83FA-DF46-47D1-8913-699C3FBE78C2Q36936920-9E75B336-99CC-4C01-B8E8-65CF76A54E00Q36936930-49DE8A04-663B-4E32-8574-B99B106DDC6DQ36949979-99F55C42-1FCE-4318-A595-A5B9A6A44220Q37193201-54FCF82B-31CB-4E61-B8BB-414AF5B734FBQ37230988-5422D25E-E9FE-454C-851B-025D86A40E03
P2860
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development
@nl
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.
@ast
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.
@en
type
label
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development
@nl
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.
@ast
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.
@en
prefLabel
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development
@nl
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.
@ast
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.
@en
P2093
P2860
P3181
P356
P1476
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.
@en
P2093
Alvin V Terry
J Warren Beach
Jerry J Buccafusco
P2860
P304
P3181
P356
10.1124/JPET.108.145292
P407
P577
2008-11-20T00:00:00Z